William Blair & Company
BBIO icon

William Blair & Company’s BridgeBio Pharma BBIO Stock Holding History

William Blair & Company’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$383K Buy
5,141
+2,123
+70% +$149K ﹤0.01% 1315
2026
Q1 		$224K Buy
+3,018
New +$219K ﹤0.01% 1438

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

William Blair & Company's BBIO Position: Q2 2026 in Review

William Blair & Company increased its BridgeBio Pharma (BBIO) stake by 70% in Q2 2026, buying an estimated $149K and bringing the position to 5,141 shares worth $383K. The position accounts for ﹤0.01% of the portfolio, ranked #1315.

William Blair & Company first reported a position in BBIO in Q1 2026 and has held it in 2 quarters since. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • William Blair & Company held 5,141 shares of BridgeBio Pharma worth $383K as of Q2 2026.
  • William Blair & Company bought 2,123 BridgeBio Pharma shares in Q2 2026, an estimated $149K.
  • BridgeBio Pharma made up ﹤0.01% of William Blair & Company's portfolio in Q2 2026, its #1315 holding.
  • William Blair & Company first reported a position in BridgeBio Pharma in Q1 2026 and has held it in 2 quarters since.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on William Blair & Company's 13F filing for Q2 2026, filed 11 Aug 2026.